Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
about
Paediatric ChordomasDurable complete response to chemotherapy in an infant with a clival chordoma.Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.Biologically targeted therapeutics in pediatric brain tumors.Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.Management of chronic myeloid leukemia in childhood.Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma.
P2860
Q26782622-814CF34D-0BB4-47AB-ADC4-96B6FDBE293CQ33274237-B8870782-8C81-4AB7-8D7F-1E9E0DA038ADQ33274900-044A13EF-17EE-43E4-8E61-9C982BFE857FQ34184430-803E5540-2051-47FA-BE88-EA0B25F87FCEQ35177853-A83E4296-5758-49BC-AB00-24A091E7A1AFQ35224485-2816B10E-A06C-4010-ADA1-7F0DD4D43D7BQ35738941-8A064CD3-AFEF-47E8-A9CB-2564C168A373Q36844744-AC857245-FC14-49EC-BD1E-8D3F84234C3DQ36936139-87A643EF-7B11-40C5-B1D7-33CB79BB6913Q37318631-BBFC3808-5590-4AA9-B0E0-24EA5946CC1DQ37991223-1E0715E6-3B03-41C4-9326-F3CFA34AE8B6Q38233425-071B55EB-1403-4CB6-8204-FE8B28B27DADQ38926034-DC813B52-D949-4D4D-9940-E5D634E65A0FQ43156043-ECC3F8D4-AB83-4675-A2DC-FC96A5DE15B8Q48761873-D1406BCA-CF61-46AC-ACF7-FB4DCBBB772C
P2860
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Target-driven exploratory stud ...... er (ITCC) European Consortium.
@ast
Target-driven exploratory stud ...... er (ITCC) European Consortium.
@en
Target-driven exploratory stud ...... apies for Children with Cancer
@nl
type
label
Target-driven exploratory stud ...... er (ITCC) European Consortium.
@ast
Target-driven exploratory stud ...... er (ITCC) European Consortium.
@en
Target-driven exploratory stud ...... apies for Children with Cancer
@nl
prefLabel
Target-driven exploratory stud ...... er (ITCC) European Consortium.
@ast
Target-driven exploratory stud ...... er (ITCC) European Consortium.
@en
Target-driven exploratory stud ...... apies for Children with Cancer
@nl
P2093
P50
P1476
Target-driven exploratory stud ...... cer (ITCC) European Consortium
@en
P2093
Anna Ndiaye
Anne Geoffray
Birgit Geoerger
Bruce Morland
Didier Frappaz
Fabienne Pichon
Francoise Boderet
Gabriel Kalifa
Gilles Vassal
Innovative Therapies for Children with Cancer European Consortium
P304
P356
10.1016/J.EJCA.2009.03.007
P577
2009-04-09T00:00:00Z